Abeona Therapeutics Inc Est. EPS Q/Q
What is the Est. EPS Q/Q of Abeona Therapeutics Inc?
The Est. EPS Q/Q of Abeona Therapeutics Inc is -82.86%
What is the definition of Est. EPS Q/Q?
Prospective quarterly EPS growth rate, year over year, is the estimated increase of the company’s EPS for the current quarter compared to performance from a past corresponding quarter.
= current quarter yoy (year over year)
The prospective EPS growth rate is a predicted estimate of the earnings per share growth rate towards the current quarter and expressed as a percentage compared to the respective past quarter. The estimated earnings per share growth rate is an important factor for judging a company's value. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
Est. EPS Q/Q of companies in the Health Care sector on NASDAQ compared to Abeona Therapeutics Inc
What does Abeona Therapeutics Inc do?
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Companies with est. eps q/q similar to Abeona Therapeutics Inc
- Trecora Resources has Est. EPS Q/Q of -83.33%
- Apollo Medical Inc has Est. EPS Q/Q of -83.33%
- Ultrapar Participacoes S.A has Est. EPS Q/Q of -83.33%
- Brooks Automation has Est. EPS Q/Q of -82.98%
- Medical Facilities has Est. EPS Q/Q of -82.93%
- Morphosys AG has Est. EPS Q/Q of -82.91%
- Abeona Therapeutics Inc has Est. EPS Q/Q of -82.86%
- Uber Technologies Inc has Est. EPS Q/Q of -82.81%
- Spirit Airlines has Est. EPS Q/Q of -82.81%
- Spirit Airlines Inc has Est. EPS Q/Q of -82.81%
- Nebius N.V has Est. EPS Q/Q of -82.76%
- Kirkland`s Inc has Est. EPS Q/Q of -82.61%
- Alkermes plc has Est. EPS Q/Q of -82.61%